We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$191M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Consumer Staples 0.52%
3 Consumer Discretionary 0.08%
4 Financials 0.04%
5 Industrials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPRX
176
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-51,200
Closed -$60K
CRIS icon
177
Curis
CRIS
$3.73M
– –
-50
Closed -$161K
ENTA icon
178
Enanta Pharmaceuticals
ENTA
$412M
– –
-17,507
Closed -$514K
FONR
179
DELISTED
Fonar
FONR
– –
-8,473
Closed -$130K
GILD icon
180
Gilead Sciences
GILD
$184B
– –
-6,024
Closed -$553K
GLMD icon
181
Galmed Pharmaceuticals
GLMD
$4.51M
– –
-52
Closed -$369K
HOLX
182
DELISTED
Hologic
HOLX
– –
-14,732
Closed -$508K
HUM icon
183
Humana
HUM
$47B
– –
-110,000
Closed -$20.1M
ICLR icon
184
Icon
ICLR
$13B
– –
-7,585
Closed -$570K
IMUX icon
185
Immunic
IMUX
$225M
– –
-75
Closed -$271K
INDP icon
186
Indaptus Therapeutics
INDP
$152M
– –
-86
Closed -$795K
IQV icon
187
IQVIA
IQV
$43B
– –
-7,447
Closed -$485K
MYGN icon
188
Myriad Genetics
MYGN
$298M
– –
-3,333
Closed -$125K
NGNE icon
189
Neurogene
NGNE
$769M
– –
-2,980
Closed -$526K
NVO
190
Novo Nordisk
NVO
$209B
– –
-233,320
Closed -$6.32M
OMER icon
191
Omeros
OMER
$1.32B
– –
-200,000
Closed -$3.07M
RGLS
192
DELISTED
Regulus Therapeutics
RGLS
– –
-2,712
Closed -$2.26M
SPY icon
193
State Street SPDR S&P 500 ETF Trust
SPY
$822B
– –
-1,600
Closed -$329K
TNDM icon
194
Tandem Diabetes Care
TNDM
$1.49B
– –
-2,500
Closed -$217K
TTNP
195
DELISTED
Titan Pharmaceuticals
TTNP
– –
0
– –
VNDA icon
196
Vanda Pharmaceuticals
VNDA
$323M
– –
-71,849
Closed -$601K
WBA
197
DELISTED
Walgreens Boots Alliance
WBA
– –
-35,292
Closed -$2.97M
ZBH icon
198
Zimmer Biomet
ZBH
$19.3B
– –
-161
Closed -$17K
NVRO
199
CALL
DELISTED
NEVRO CORP.
NVRO
– –
-100,000
Closed -$5.63M
TARO
200
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
– –
-3,429
Closed -$491K
5 6 7
8
9

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $191M of net new capital in Q2 2016, opening 57 new positions and adding to 37 existing holdings. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $12.4M trimmed.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.